Do you want to read an article? Please log in or register.
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Thrombosis and Stroke
Related content
Atrial Fibrillation
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
Clin Res Cardiol.
Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH
doi: 10.1007/s00392-019-01594-9.
Atrial Fibrillation
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Lancet.
Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A
doi: 10.1016/S0140-6736(19)31872-0.
Atrial FibrillationThrombosis and Stroke
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
J Am Heart Assoc.
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP
doi: 10.1161/JAHA.117.007633.
COMMENTED
Atrial Fibrillation
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial
★ 3
Recommended and commented by
Prof. Dr Sacha P. Salzberg, Faculty Member
doi: 10.1001/jama.2019.21187.
Atrial Fibrillation
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial
Eur Heart J.
Haldar S, Khan HR, Boyalla V, Kralj-Hans I, Jones S, Lord J, Onyimadu O, Satishkumar A, Bahrami T, De Souza A, Clague JR, Francis DP, Hussain W, Jarman JW, Jones DG, Chen Z, Mediratta N, Hyde J, Lewis M, Mohiaddin R, Salukhe TV, Murphy C, Kelly J, Khattar RS, Toff WD, Markides V, McCready J, Gupta D, Wong T, CASA-AF Investigators
doi: 10.1093/eurheartj/ehaa658.
Atrial FibrillationHeart, Artery and Coronary Diseases
The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials
Circulation.
Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, Brueckmann M, Kleine E, Ten Berg JM
doi: 10.1161/CIRCULATIONAHA.
Atrial Fibrillation
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial
Clin Res Cardiol.
Goette A, Merino JL, De Caterina R, Huber K, Heidbuchel H, Jin J, Lip GYH
doi: 10.1007/s00392-020-01635-8.
Atrial FibrillationTherapy and Intervention
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
N Engl J Med.
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators
doi: 10.1056/NEJMoa1701005.
Atrial Fibrillation
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials
Eur Heart J Acute Cardiovasc Care.
Zelniker TA, Ruff CT, Antman EM, Giugliano RP
doi: 10.1177/2048872618796990.